The proportion of patients achieving a prostate-specific antigen nadir less than or equal to 0.2 ng/ml was exactly the same for patients treated with transdermal estradiol patches and those treated ...

Based on phase 3 trial findings, investigators conclude that transdermal estradiol should be a standard of care ADT option for patients with nonmetastatic prostate cancer. Transdermal estradiol (tE2) ...

Bethesda, MD - In a head-to-head crossover comparison, oral estrogen therapy (ET) was associated with a sustained increase in the inflammatory marker C-reactive protein (CRP) among postmenopausal ...

December 9, 2011 — Voting in favor of the norelgestromin/ethinyl estradiol transdermal contraceptive patch (Ortho Evra, Jannsen), a US Food and Drug Administration (FDA) advisory panel today ...